Platform Comparison · July 2026
BioMate AI vs. Claude Science vs. Biomni vs. Robin & Finch vs. GPT-5.5
A comparison of AI platforms for biomedical research — capabilities, benchmarks, and intended use.
Five distinct platforms for AI-assisted biomedical research launched within twelve months of each other. Each takes a different approach: execution infrastructure, research workbench, autonomous agent, discovery system, or foundation model. This comparison covers what each actually does, where each performs, and how they differ.
The Five Platforms at a Glance
Natural-language interface to 4,000+ indexed workflows, 60+ live scientific databases, and literature synthesis. Executes analyses on AWS Batch, enforces QC gates, and delivers audit-ready outputs including IND sections and CRO packages.
Commercial · Free tier availableAI research workbench with specialists for genomics, scRNA-seq, proteomics, and cheminformatics; connects to 60+ scientific databases; generates figures and manuscripts.
Beta · Grant program openGeneral-purpose biomedical AI agent using ReAct-style reasoning over LLMs, retrieval, and tool calls across diverse biomedical task types.
Open-source · ResearchMulti-agent system for autonomous drug discovery. Crow/Falcon handle literature retrieval via PaperQA2; Finch runs RNA-seq and flow cytometry analysis in Docker.
Nonprofit · Research / Open-sourceFoundation model family for life sciences. GPT-Rosalind specializes in drug discovery, genomics, and protein reasoning. Strong general reasoning; no built-in execution layer.
Commercial API · ChatGPT for HealthcareBenchmark Evaluation
The benchmarks below use published standardized datasets where multiple systems have been evaluated and scores are verifiable. Each section includes a description of the benchmark, citation, task count, and scoring scale.
BixBench — agentic computational biology (FutureHouse + ScienceMachine, 2025)
What it measures: 54 capsules / 205 tasks derived from published computational biology analyses. Agents must reproduce the original analytical conclusions (gene lists, statistical outputs, structural comparisons) from raw data. Open-answer, LLM-judge graded. Scale: 0–100%, task-level pass/fail aggregated. Citation: FutureHouse BixBench leaderboard (llm-stats.com/benchmarks/bixbench); saturation paper bioRxiv 2026.04.28.721523.
BiomniEval1 — biomedical knowledge and reasoning (Stanford SNAP, 2025)
What it measures: 223 tasks across 5 biomedical subtasks: GWAS causal gene identification (Open Targets API), GWAS variant association (GWAS Catalog), rare disease diagnosis (OMIM/ClinVar), patient gene prioritization, and CRISPR screen hit identification. Scale: Exact-match accuracy per subtask; overall = mean across all 223 tasks. Citation: Biomni preprint, bioRxiv 2025 (PMC12157518); benchmark tasks available at SNAP-Stanford/Biomni.
LABBench — CloningScenarios (Jansen et al., 2025)
What it measures: 33 multiple-choice molecular cloning problems covering restriction enzyme digest, Gibson assembly, Golden Gate assembly, and gRNA spacer design. Requires precise biochemistry knowledge: fragment sizes, overhang sequences, enzyme compatibility. Scale: % correct (4-choice MCQ). Citation: Jansen et al., LABBench: A Challenging Benchmark for AI in Biological Research (2025). The original paper reports evaluation results for foundation LLM baselines (including Claude 3.5 Sonnet); BioMate's score reflects BioMate's own evaluation run against the published LABBench dataset (April 2026).
BioMate platform benchmarks (April 2026)
What it measures: Task-specific datasets measuring core execution capabilities: workflow routing accuracy (120 queries across 36 domains), prerequisite parameter auto-recovery, and parameter prefill accuracy. These benchmarks have no published external comparators as they test BioMate-specific features. Scale: % correct per task set.
Summary
BioMate AI is a production workflow execution platform with validated performance in ADMET prediction, PBPK modeling, and regulatory document assembly. It is suited for drug discovery teams that need results delivered as audit-ready outputs, including IND sections and CRO packages with GxP compliance alignment.
Claude Science is a research workbench designed for academic and early-stage R&D — useful for analysis, literature synthesis, and manuscript preparation across multiple scientific domains.
Biomni is an open-source research agent capable of handling a broad range of biomedical reasoning tasks without task-specific configuration, making it a flexible tool for exploratory research.
Robin + Finch is a multi-agent system oriented toward autonomous hypothesis-to-validation cycles in drug discovery, with a focus on literature retrieval and omics data analysis.
GPT-5.5 / Rosalind are foundation models that provide strong general biomedical reasoning and can serve as the LLM backbone for custom pipelines and tools.
Sources
- Anthropic — Claude Science, an AI workbench for scientists (June 30, 2026)
- Hu et al. — Biomni: A General-Purpose Biomedical AI Agent, NIH PMC (2025)
- Hu et al. — Biomni preprint, bioRxiv (May 2025)
- FutureHouse — Demonstrating end-to-end scientific discovery with Robin, Nature (2026)
- BixBench leaderboard — llm-stats.com (FutureHouse + ScienceMachine, 2025–2026)
- FutureHouse — BixBench benchmark announcement
- Saturation paper — BixBench skill-based saturation analysis, bioRxiv (April 2026)
- Jansen et al. — LABBench: A Challenging Benchmark for AI in Biological Research, FutureHouse (2025)
- OpenAI — Introducing GPT-5.5
- BioMate AI — Benchmark evaluation matrix and platform evaluation suite (April 2026)